Fecal Calprotectin Test Market to Reach USD 4,687.1 Million by 2032 as Non-Invasive Diagnostics Gain Ground

As gastrointestinal disorders climb globally, clinicians are leaning more heavily on a simple stool-based test to avoid unnecessary colonoscopies. According to a recent fecal calprotectin test market report, the global industry was valued at USD 2,865.3 million in 2024 and is projected to grow from USD 3,026.2 million in 2025 to USD 4,687.1 million by 2032, reflecting a compound annual growth rate of 6.45% over the forecast period.

Fecal calprotectin testing measures a protein biomarker released by white blood cells during intestinal inflammation, offering clinicians a non-invasive way to detect and monitor conditions like inflammatory bowel disease (IBD) — including Crohn's disease and ulcerative colitis. The two primary testing formats are enzyme-linked immunosorbent assay (ELISA), which dominates lab-based testing, and lateral flow immunoassay, which is gaining ground in point-of-care settings.

Rising IBD Prevalence Is the Core Growth Driver

Chronic gastrointestinal conditions, particularly Crohn's disease and ulcerative colitis, are becoming more common globally, especially in developed regions where changing dietary patterns and lifestyle factors play a role. The U.S. Centers for Disease Control and Prevention reported in 2024 that IBD prevalence in the United States ranged between 2.4 million and 3.1 million cases, with impact varying across demographic groups.

Because IBD requires timely diagnosis and ongoing monitoring, healthcare providers increasingly favor fecal calprotectin testing as a reliable biomarker for intestinal inflammation — one that reduces reliance on invasive colonoscopies and improves patient compliance with routine monitoring. This diagnostic value underpins much of the market's steady growth trajectory.

Cost Remains a Barrier to Wider Access

Despite its clinical value, the high cost of testing — driven by specialized equipment, reagents, and the need for trained personnel — continues to limit accessibility in regions with constrained healthcare budgets. This affordability gap is especially pronounced in low-income areas, where broader patient populations may lack access to timely gastrointestinal diagnostics altogether.

Industry efforts to close this gap center on developing more cost-effective, simplified testing methods that reduce dependence on expensive infrastructure and specialized labor. Rising competition among diagnostic manufacturers and continued technological advancement are expected to gradually push prices down while expanding accessibility across diverse healthcare settings.

Point-of-Care Testing Is Changing Where Diagnosis Happens

One of the most consequential shifts underway is the move toward point-of-care fecal calprotectin assays, which eliminate the need for centralized laboratory processing and dramatically cut turnaround time. These portable, user-friendly, cost-effective tests let healthcare professionals deliver rapid, on-site results in clinics, hospitals, and even remote settings — a meaningful improvement for patients who previously faced long waits for lab-based results.

In February 2025, BIOHIT partnered with Celltrion Healthcare UK to supply point-of-care assays for the Celltrion Connect Dedicated Homecare Service, including the Preventis SmarTest Calprotectin Home test — a digital self-test system designed for remote IBD monitoring. This kind of home-testing capability represents a meaningful step toward decentralized, patient-driven disease management.

Segment Breakdown

By test type, ELISA-based assays led the market with USD 1,658.5 million in 2024 revenue, owing to their high sensitivity and suitability for quantitative analysis in clinical laboratory settings, though lateral flow immunoassays continue gaining share for point-of-care use. By application, IBD diagnosis represents the largest category, holding 36.99% share in 2024, fueled by rising global IBD prevalence and growing preference for non-invasive diagnostics over colonoscopy. By end user, diagnostic laboratories are projected to reach USD 2,254.2 million by 2032, supported by rising testing volumes and improved infrastructure.

Regional Dynamics

North America leads the global market with a 36.73% share worth USD 1,052.4 million in 2024, driven by a high prevalence of inflammatory bowel disease and widespread clinical adoption of non-invasive diagnostics. Advanced healthcare infrastructure, strong reimbursement frameworks, and the presence of major diagnostic companies all reinforce the region's dominant position. In January 2025, Sysmex America signed an agreement with Sentinel Diagnostics to distribute and service the SENTiFIT 270 and SENTiFIT 800 analyzers in Canada, supporting colorectal cancer screening alongside fecal calprotectin and occult blood testing.

Asia Pacific is projected to grow fastest, at a 7.45% CAGR, propelled by rising gastrointestinal disease prevalence, growing healthcare spending, and improving access to diagnostic technologies. Governments across the region are investing in healthcare modernization while private players expand laboratory networks, and growing public awareness of early screening is driving higher test adoption across both urban and emerging healthcare markets.

Regulatory Landscape

In the United States, fecal calprotectin tests are regulated by the FDA as in vitro diagnostic devices and must pass through the 510(k) premarket notification process to demonstrate substantial equivalence to an existing predicate device. In Europe, these tests fall under the In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746, requiring manufacturers to meet strict safety, clinical evidence, and performance evaluation standards. In Japan, the Pharmaceuticals and Medical Devices Agency oversees approval under the Pharmaceutical and Medical Device Act, requiring clinical data submission and quality control documentation.

Competitive Landscape

Key companies operating in the market include ALPCO, ORGENTEC Diagnostika, EagleBio, F. Hoffmann-La Roche, Alpha Laboratories, DiaSorin, Immundiagnostik, BÜHLMANN, Epitope Diagnostics, Thermo Fisher Scientific, Biohit Oyj, Svar Life Science, Abbott, DRG Instruments, and Sysmex Corporation. Competitive strategy centers on developing higher-sensitivity, automation-compatible assay platforms while expanding regulatory approvals and clinical partnerships to broaden geographic reach. In July 2024, Eurofins Scientific began performing stool calprotectin testing onsite at its Dublin facility — the first local offering of the test in the country — while ALPCO announced the European commercial launch of its FDA 510(k)-cleared Calprotectin Immunoturbidimetric Assay in May 2025, alongside enrollment of the first patient in a pivotal U.S. clinical trial for an automated chemiluminescent version.

Outlook

With inflammatory bowel disease prevalence climbing and healthcare systems worldwide prioritizing non-invasive diagnostic pathways, the fecal calprotectin test market is positioned for steady, sustained expansion. The next phase of growth is likely to be defined by the industry's ability to shrink the cost gap through point-of-care innovation, extending reliable IBD monitoring to patients and healthcare settings that have historically been priced out of regular testing.